Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Aptevo Therapeutics Inc (APVO)

Aptevo Therapeutics Inc (APVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,939
  • Shares Outstanding, K 18,512
  • Annual Sales, $ 0 K
  • Annual Income, $ -17,410 K
  • EBIT $ -25 M
  • EBITDA $ -24 M
  • 60-Month Beta 5.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.12
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -12.10
  • Most Recent Earnings $-0.48 on 11/07/24
  • Next Earnings Date 11/12/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.28
  • Number of Estimates 1
  • High Estimate -0.28
  • Low Estimate -0.28
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.03%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2022 +36.00%
on 11/18/24
0.3533 -22.16%
on 10/29/24
-0.0786 (-22.23%)
since 10/22/24
3-Month
0.1380 +99.28%
on 10/14/24
0.5150 -46.60%
on 10/22/24
-0.1056 (-27.75%)
since 08/22/24
52-Week
0.1380 +99.28%
on 10/14/24
10.8000 -97.45%
on 03/07/24
-8.0850 (-96.71%)
since 11/22/23

Most Recent Stories

More News
Aptevo Highlights the Potential of the Company's Robust Portfolio in Cancer Immunotherapy, the Success of Bispecifics as a Category, and Their Growing Importance in the Oncology Treatment Paradigm

Developing innovative bispecific antibodies for monotherapy and combination with the potential to expand the frontiers of cancer treatment

APVO : 0.2700 (+1.20%)
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies

Potential to redefine frontline AML treatment being evaluated in clinic: Mipletamig, CD3 x CD123 bispecific, in combination with standard of care, offers a multi-mechanism strategy for potential improved...

APVO : 0.2700 (+1.20%)
Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia (AML) Trial Initiated

Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidine

APVO : 0.2700 (+1.20%)
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia

Cohort 1 Combination Therapy Arm Shows 36% Remission Rate Among Response-evaluable Patients Treated to Date

APVO : 0.2700 (+1.20%)
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

SEATTLE, WA / ACCESSWIRE / May 12, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics...

APVO : 0.2700 (+1.20%)
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting

Preclinical Data Support Potential for APVO442 in Difficult-to-Treat Types of Prostate Cancer, Including Metastatic Castration-Resistant Disease SEATTLE, WA / ACCESSWIRE / April 12, 2022 / Aptevo Therapeutics...

APVO : 0.2700 (+1.20%)
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia

Patients in Both Monotherapy and Combination Arms in Multi-Cohort Trial Have Achieved Transplant Eligible Status SEATTLE, WA / ACCESSWIRE / March 29, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage...

APVO : 0.2700 (+1.20%)
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update

SEATTLE, WA / ACCESSWIRE / March 24, 2022 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary...

APVO : 0.2700 (+1.20%)
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update

APVO436 Phase 1b Trial for Acute Myeloid Leukemia Adds New Site Complete Remission Patient to Advance to Transplant SEATTLE, WA / ACCESSWIRE / February 9, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the...

APVO : 0.2700 (+1.20%)
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022

Vice Chairman, John E. Niederhuber, M.D., to Assume Chairmanship, Effective April 1, 2022 SEATTLE, WA / ACCESSWIRE / January 21, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO),...

APVO : 0.2700 (+1.20%)

Business Summary

Aptevo Therapeutics Inc. is a biotechnology company which focused on developing oncology and hematology therapeutics. The company's platform consists of ADAPTIR(TM). Its product pipeline includes WinRho (R) SDF, HepaGam B (R), VARIZIG(R) and IXINITY (R) which are in pre-clinical stage. Aptevo Therapeutics...

See More

Key Turning Points

3rd Resistance Point 0.3142
2nd Resistance Point 0.3020
1st Resistance Point 0.2844
Last Price 0.2700
1st Support Level 0.2546
2nd Support Level 0.2424
3rd Support Level 0.2248

See More

52-Week High 10.8000
Fibonacci 61.8% 6.7271
Fibonacci 50% 5.4690
Fibonacci 38.2% 4.2109
Last Price 0.2700
52-Week Low 0.1380

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar